• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Tissue Inhibitor of Metalloproteinase-1 Is Increased in Chagasic Cardiomyopathy
Am J Trop Med Hyg. 2021 Jul 19:tpmd200401. doi: 10.4269/ajtmh.20-0401. Online ahead of print.ABSTRACTChagas disease (CD) mainly conveys stroke risk through structural cardiac disease. However, stroke and cognitive impairment are seen in CD independently of cardiac disease severity. Chronic inflammation may be an explanation for this association, because inflammation plays an important role in the pathogenesis of acute ischemic stroke and dementia. In the present study, we selected five candidate biomarkers for Chagas disease: interleukin-6, membrane metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (TIMP1), oros...
Source: The American Journal of Tropical Medicine and Hygiene - July 19, 2021 Category: Tropical Medicine Authors: Karina Oliveira Garcia Thiago Cerqueira Silva Maria do Carmo Pereira Nunes Iuri Ferreira Felix Murilo Araujo Oliveira Maria Eduarda Lisboa Marques Leila Souza Brito Santos Paulo Roberto Sampaio Peixoto Sousa Pedro Jos é Ramiro Muiños Renata Martins Maia Source Type: research

Role of FAK signaling in chagasic cardiac hypertrophy.
Abstract Cardiac hypertrophy and dysfunction are a significant complication of chronic Chagas disease, with heart failure, stroke, and sudden death related to disease progression. Thus, understanding the signaling pathways involved in the chagasic cardiac hypertrophy may provide potential targets for pharmacological therapy. Herein, we investigated the implication of focal adhesion kinase (FAK) signaling pathway in triggering hypertrophic phenotype during acute and chronic T. cruzi infection. C57BL/6 mice infected with T. cruzi (Brazil strain) were evaluated for electrocardiographic (ECG) changes, plasma levels of...
Source: Braz J Infect Dis - September 11, 2020 Category: Infectious Diseases Authors: Tucci AR, Oliveira FOR, Lechuga GC, Oliveira GM, Eleuterio AC, Mesquita LB, Farani PSG, Britto C, Moreira OC, Pereira MCS Tags: Braz J Infect Dis Source Type: research

Simvastatin improves cardiac function through Notch1 activation in BALB/c mice with chronic Chagas cardiomyopathy.
Conclusions and Implications: Simvastatin, probably acting through the Notch1 pathway, decreases inflammation, improving cardiac function in chronically T. cruzi-infected mice. PMID: 32393497 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - May 10, 2020 Category: Microbiology Authors: Guzmán-Rivera D, Liempi A, González-Herrera F, Fuentes S, Carrillo I, Abarca P, Castillo C, Kemmerling U, Pesce B, Maya JD Tags: Antimicrob Agents Chemother Source Type: research

Case Report: Malignant Ventricular Arrhythmias Mimicking Acute Coronary Syndrome in Chagas Disease.
Abstract Chronic Chagas heart disease has different clinical manifestations including arrhythmias, heart failure, and stroke. Chest pain is one of the most common symptoms and when associated with changes in the electrocardiogram, such as T-wave changes, electrically inactive areas, and segmental wall motion abnormalities, may lead to a misdiagnosis of acute coronary syndrome (ACS). Here, we describe two patients with Chagas heart disease and syncope due to sustained ventricular tachycardia who were misdiagnosed with ACS, and discuss the role of novel imaging modalities in the differential diagnosis and risk strat...
Source: The American Journal of Tropical Medicine and Hygiene - February 9, 2020 Category: Tropical Medicine Authors: Moll-Bernardes RJ, Saraiva RM, Sarmento de Oliveira R, Tavares Pinheiro MV, Camargo GC, Xavier de Brito AS, Altino de Almeida S, Siqueira FPR, de Souza Nogueira Sardinha Mendes F, Barbosa RM, Xavier SS, Rosado de Castro PH, Silvestre de Sousa A Tags: Am J Trop Med Hyg Source Type: research

Electrocardiogram in Chagas disease
Abstract Since the initial descriptions of Chagas cardiomyopathy (ChCM), the electrocardiography has played a key role in patient evaluations. The diagnostic criterion of chronic ChCM is the presence of characteristic electrocardiographic (ECG) abnormalities in seropositive individuals, regardless of the presence of symptoms. However, these ECG abnormalities are rarely specific to ChCM and, particularly among the elderly, can be caused by other simultaneous cardiomyopathies. ECG abnormalities can predict the occurrence of heart failure, stroke, and even death. Nevertheless, most prognostic studies have included Chagas dise...
Source: Revista da Sociedade Brasileira de Medicina Tropical - October 8, 2018 Category: Tropical Medicine Source Type: research

A protocol update for the Selenium Treatment and Chagasic Cardiomyopathy (STCC) trial
Several studies evaluating clinical forms of chronic Chagas disease show that about one-third of patients present cardiac involvement. Heart failure, sudden death and cardioembolic stroke are the main mechanis...
Source: Trials - September 19, 2018 Category: General Medicine Authors: Marcelo Teixeira Holanda, Mauro Felippe Felix Mediano, Alejandro Marcel Hasslocher-Moreno, S érgio Salles Xavier, Roberto Magalhães Saraiva, Andrea Silvestre Sousa, Erica Rodrigues Maciel, Fernanda Martins Carneiro, Paula Simplicio da Silva, Luiz Henriq Tags: Update Source Type: research

Chagas Disease and Stroke: Frequency and Clinical Correlates (P3.235)
Conclusions: Patients presenting with stroke and CD had more cardiac impairment and cardioembolic events than non-CD patients. Better healthcare of stroke patients and CD is required as these patients were readmitted more frequently than those without CDDisclosure: Dr. Meira has nothing to disclose. Dr. Teixeira has nothing to disclose. Dr. Nunes has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Meira, F., Teixeira, A., Nunes, M. d. C. Tags: Stroke in the Young Source Type: research

The potential influence of atherogenic dyslipidemia on the severity of chronic Chagas heart disease
Conclusion: we observed that AI correlated with CCHD stages and contributed, in association with anti-B13 antibodies and age, to the prediction of systolic heart failure.RESUMO Introducción: la miocardiopatía chagásica (MCC) es la manifestación más común de la tripanosomiasis americana, causando cerca de 50.000 muertes al año. Varios factores se asocian con la gravedad de MCC. Sin embargo, la evaluación de la contribución de los principales factores de riesgo cardiovascular (FRC), como la hipertensión y la dislipidemia aterogénica (DA), a la gravedad de la MCC es escasa, a pesar de su papel bien establecido en l...
Source: Revista da Associacao Medica Brasileira - March 23, 2016 Category: Journals (General) Source Type: research

Developments in the management of Chagas cardiomyopathy.
Authors: Tanowitz HB, Machado FS, Spray DC, Friedman JM, Weiss OS, Lora JN, Nagajyothi J, Moraes DN, Garg NJ, Nunes MC, Ribeiro AL Abstract Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, incl...
Source: Expert Review of Cardiovascular Therapy - February 17, 2016 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Rivaroxaban for treatment of intraventricular thrombus in Chagas disease
We present a case of a 61-year-old man admitted for stroke 5 months after a renal embolism. An intraventricular thrombus was observed, probably the source of the cerebral and renal embolisms. The patient refused warfarin and rivaroxaban was used instead. After 40 days of treatment the thrombus had dissolved, after 20 months of regular use of rivaroxaban no more embolic events were observed. The use of rivaroxaban was effective in preventing embolic events in Chagas disease and intraventricular thrombus. <Learning objective: Warfarin is recommended for stroke prevention in patients with Chagas disease and left ventri...
Source: Journal of Cardiology Cases - January 12, 2016 Category: Cardiology Source Type: research

Chagas disease as a cause of heart failure and ventricular arrhythmias in patients long removed from endemic areas: an emerging problem in Europe
We report two examples of Chagas cardiomyopathy in South American women permanently residing in Italy for more than 20 years, presenting with cardiac manifestations ranging from left ventricular dysfunction and heart failure to isolated ventricular arrhythmias. The present review emphasizes that Chagas disease should be considered as a potential diagnosis in patients from endemic areas presenting with ‘idiopathic’ cardiac manifestations, even when long removed from their country of origin, with potential implications for treatment and control of Chagas disease transmission.
Source: Journal of Cardiovascular Medicine - October 30, 2015 Category: Cardiology Tags: Arrhythmias Source Type: research

Pages: 1  2  3